By Chris Wack
CervoMed shares were up 28% to $8.27 after the company said it saw positive results from a Phase 2b trial for neflamapimod.
The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies.
The Boston-based company said it is now focusing on reporting the results from a 32-week extension phase in the second half of 2025, and on discussing next steps on Phase 3 trial design with regulatory authorities.
Initial safety, biomarker and pharmacokinetic data from an ongoing trial in patients with a mild-to-moderate form of the disease, who are being treated with a twice-daily regimen of neflamapimod in the study, is expected to be available in the fourth quarter.
CervoMed also said that as of Dec. 31 it had $38.9 million in cash, cash equivalents and marketable securities, compared with $7.8 million as of Dec. 31, 2023. This increase was primarily attributable to the upfront proceeds received in CervoMed's private placement completed in April 2024, the company said.
Based on its current operating plan, CervoMed believes its cash, cash equivalents and marketable securities on hand will enable it to fund its planned operating expenses and capital-expenditure requirements into mid-2026.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 17, 2025 12:59 ET (16:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。